Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TIMOTHY ALAN RICHARDSON

Allopathic & Osteopathic Physicians Urology

NPI
1508985417
CMS profile
633917
Location
WICHITA, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$65,226.86

101 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 101 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TIMOTHY ALAN RICHARDSON

NPI 1508985417 · CMS profile ID 633917

Allopathic & Osteopathic Physicians / Urology

WICHITA, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 101 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1508985417?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TIMOTHY ALAN RICHARDSON, NPI 1508985417, CMS profile ID 633917. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 101 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508985417?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). TIMOTHY ALAN RICHARDSON, NPI 1508985417, CMS profile ID 633917. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 101 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508985417?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
TIMOTHY ALAN RICHARDSON, NPI 1508985417, CMS profile ID 633917, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 101 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1508985417?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

101 matching records · $65,226.86 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 101 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 101.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Astellas Pharma US Inc $1,625.0008/17/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821513713 CMS
Astellas Pharma US Inc $14.3808/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821513707 CMS
PFIZER INC. $12.8008/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832778117 CMS
Myovant Sciences Inc. $368.4807/23/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834984761 CMS
Myovant Sciences Inc. $5,525.0007/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834984767 CMS
Astellas Pharma US Inc $15.1307/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821513701 CMS
Myovant Sciences Inc. $119.6207/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834984757 CMS
Dendreon Pharmaceuticals LLC $18.8907/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851431315 CMS
Dendreon Pharmaceuticals LLC $238.0707/13/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851431317 CMS
Dendreon Pharmaceuticals LLC $5,400.0007/13/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851431319 CMS
Merck Sharp & Dohme Corporation $24.6807/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848375165 CMS
Blue Earth Diagnostics Limited $17.6607/06/2021 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 844625563 CMS
Myovant Sciences Inc. $1,300.0007/02/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834984753 CMS
Janssen Biotech, Inc. $1,000.0006/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788333941 CMS
Clarus Therapeutics Inc. $74.7006/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855012449 CMS
PFIZER INC. $12.8906/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832627011 CMS
Astellas Pharma US Inc $14.7506/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821513695 CMS
Bayer HealthCare Pharmaceuticals Inc. $705.0006/04/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789096425 CMS
Astellas Pharma US Inc $11.8405/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821513689 CMS
AbbVie Inc. $11.5905/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795827951 CMS
Bayer HealthCare Pharmaceuticals Inc. $934.0005/20/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789154637 CMS
Janssen Biotech, Inc. $14.4905/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788333963 CMS
Astellas Pharma US Inc $13.6905/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821513683 CMS
Bayer HealthCare Pharmaceuticals Inc. $1,401.0005/05/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789152969 CMS
Dendreon Pharmaceuticals LLC $19.5005/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851431313 CMS
Exelixis Inc. $1,980.0005/04/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838867261 CMS
Amgen Inc. $19.6905/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825838261 CMS
Janssen Biotech, Inc. $1,000.0005/03/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788333943 CMS
Janssen Biotech, Inc. $1,000.0005/03/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788333945 CMS
Bayer HealthCare Pharmaceuticals Inc. $934.0004/22/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789190295 CMS
Myovant Sciences Inc. $92.5604/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834984751 CMS
Myriad Genetic Laboratories, Inc. $17.5204/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834566943 CMS
Astellas Pharma US Inc $13.3704/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821513677 CMS
PFIZER INC. $29.7604/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832566651 CMS
Olympus America Inc. $11.6004/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 800267051 CMS
Bayer HealthCare Pharmaceuticals Inc. $467.0003/29/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789100973 CMS
Bayer HealthCare Pharmaceuticals Inc. $1,512.0003/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789191389 CMS
Merck Sharp & Dohme Corporation $23.6403/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848503095 CMS
UROGEN PHARMA, INC. $12.8703/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826678699 CMS
Bayer HealthCare Pharmaceuticals Inc. $705.0003/11/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789040703 CMS
Janssen Biotech, Inc. $15.3903/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788333961 CMS
Myovant Sciences Inc. $1,300.0003/04/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834984746 CMS
Allergan, Inc. $12.6002/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792920515 CMS
Blue Earth Diagnostics Limited $16.8502/26/2021 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 844625547 CMS
Bayer HealthCare Pharmaceuticals Inc. $3,960.0002/25/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789061109 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $23.0702/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851935179 CMS
Astellas Pharma US Inc $13.7702/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821513671 CMS
Astellas Pharma US Inc $1,410.0002/18/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821513665 CMS
Bayer HealthCare Pharmaceuticals Inc. $934.0002/04/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789150749 CMS
Astellas Pharma US Inc $1,410.0001/21/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821513659 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $86,175.75 176
PY2020 $69,608.84 94
PY2021 $65,226.86 101
PY2022 $108,241.77 145
PY2023 $54,108.18 92
PY2024 $52,234.60 100
PY2025 $57,472.25 94

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,011,167.14 102
PY2024 Principal investigator $1,135,170.18 154
PY2023 Principal investigator $885,930.30 110
PY2022 Principal investigator $756,095.87 23
PY2021 Principal investigator $562,671.79 35
PY2020 Principal investigator $254,093.18 91
PY2019 Principal investigator $160,394.28 110

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

102 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $7,597.08 12/31/2025 Non-covered Recipient Entity
Wichita Urology Group
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High-risk Non-muscle-Invasive Bladder Cancer NMIBC Unresponsive to Bacillus Calmett No dispute reported 06/30/2026 1232925203
Principal investigator 1 Merck Sharp & Dohme LLC $37,491.28 12/31/2025 Non-covered Recipient Entity
Wichita Urology Group
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i No dispute reported 06/30/2026 1232926745
Principal investigator 1 Janssen Research & Development, LLC $55,650.00 12/29/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175380437
Principal investigator 1 Janssen Research & Development, LLC $5,247.00 12/29/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175380675
Principal investigator 1 Janssen Research & Development, LLC $9,027.00 12/22/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175380293
Principal investigator 1 Novartis Pharmaceuticals Corporation $24,000.00 12/18/2025 Non-covered Recipient Entity
Urology Group Wichita
A two-part, Phase 1 dose escalation and expansion followed by a randomized, open-label multicenter, Phase 2 study to assess the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) vs standard of care in patients w No dispute reported 06/30/2026 1190305043
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,475.00 11/12/2025 Non-covered Recipient Entity
Wichita Urology Group PA
BAY 1841788, Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients No dispute reported 06/30/2026 1225419749
Principal investigator 1 Janssen Research & Development, LLC $8,156.00 11/07/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175380164
Principal investigator 1 Sumitomo Pharma America, Inc. $1,252.50 11/05/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP PA
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176654641
Principal investigator 1 Sumitomo Pharma America, Inc. $2,505.00 11/05/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP PA
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176654690
Principal investigator 1 Sumitomo Pharma America, Inc. $1,252.50 11/05/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP PA
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176655064
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,236.20 10/27/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP, PA
A two-part, Phase 1 dose escalation and expansion followed by a randomized, open-label multicenter, Phase 2 study to assess the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) vs standard of care in patients w No dispute reported 06/30/2026 1190303925
Principal investigator 1 Janssen Research & Development, LLC $382.00 10/13/2025 Non-covered Recipient Entity
XCANCER OMAHA LLC
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy No dispute reported 06/30/2026 1175347013
Principal investigator 1 Janssen Research & Development, LLC $473.00 10/13/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175380650
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,415.10 10/05/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP, PA
TulmiSTAR-02: A Two-part Phase I Dose Escalation Study of Tulmimetostat (DZR123) in Combination With Darolutamide or Abiraterone Followed by Open-label, Randomized, Phase II Dose Expansion Study to Assess the Safety and Efficacy of Tulmimetostat in Combin No dispute reported 06/30/2026 1190303927
Principal investigator 1 Janssen Research & Development, LLC $14,222.00 10/03/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175380503
Principal investigator 1 Janssen Research & Development, LLC $35,602.00 10/02/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175380665
Principal investigator 1 Janssen Research & Development, LLC $37,692.00 09/08/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380195
Principal investigator 1 Janssen Research & Development, LLC $13,482.00 09/08/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175380225
Principal investigator 1 Janssen Research & Development, LLC $225.00 09/08/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175380415
Principal investigator 1 Merck Sharp & Dohme LLC $313.08 08/31/2025 Non-covered Recipient Entity
Wichita Urology Group
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i No dispute reported 06/30/2026 1232926791
Principal investigator 1 Janssen Research & Development, LLC $120.00 08/28/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175380301
Principal investigator 1 Janssen Research & Development, LLC $533.00 08/18/2025 Non-covered Recipient Entity
XCANCER OMAHA LLC
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy No dispute reported 06/30/2026 1175346617
Principal investigator 1 Janssen Research & Development, LLC $14,897.00 08/11/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175380478
Principal investigator 1 Janssen Research & Development, LLC $225.00 08/07/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175380257
Principal investigator 1 Janssen Research & Development, LLC $225.00 08/07/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175380444
Principal investigator 1 Janssen Research & Development, LLC $30.00 08/07/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175380463
Principal investigator 1 Janssen Research & Development, LLC $706.00 08/04/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175380189
Principal investigator 1 Janssen Research & Development, LLC $706.00 08/04/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175380523
Principal investigator 1 Sumitomo Pharma America, Inc. $1,252.50 08/01/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP PA
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176641845
Principal investigator 1 Janssen Research & Development, LLC $42,548.00 07/28/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380719
Principal investigator 1 Janssen Research & Development, LLC $200.00 07/18/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380242
Principal investigator 1 Janssen Research & Development, LLC $791.00 07/18/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380421
Principal investigator 1 Janssen Research & Development, LLC $541.00 07/18/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380539
Principal investigator 1 Janssen Research & Development, LLC $1,702.00 07/18/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380561
Principal investigator 1 Janssen Research & Development, LLC $200.00 07/18/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380570
Principal investigator 1 Janssen Research & Development, LLC $541.00 07/18/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380592
Principal investigator 1 Janssen Research & Development, LLC $200.00 07/18/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380599
Principal investigator 1 Janssen Research & Development, LLC $791.00 07/18/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380609
Principal investigator 1 Janssen Research & Development, LLC $541.00 07/18/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380632
Principal investigator 1 Janssen Research & Development, LLC $200.00 07/18/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380682
Principal investigator 1 Janssen Research & Development, LLC $200.00 07/18/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380728
Principal investigator 1 Sumitomo Pharma America, Inc. $1,252.50 07/09/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP PA
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176640261
Principal investigator 1 Sumitomo Pharma America, Inc. $1,252.50 07/09/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP PA
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176640326
Principal investigator 1 Sumitomo Pharma America, Inc. $2,505.00 07/09/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP PA
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176640403
Principal investigator 1 Janssen Research & Development, LLC $13,542.00 07/07/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175380211
Principal investigator 1 Janssen Research & Development, LLC $22,552.00 07/07/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380348
Principal investigator 1 Janssen Research & Development, LLC $225.00 07/07/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175380546
Principal investigator 1 Janssen Research & Development, LLC $225.00 07/07/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175380761
Principal investigator 1 Janssen Research & Development, LLC $34,275.00 06/30/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175380330
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $676.50 06/12/2025 Non-covered Recipient Entity
Wichita Urology Group PA
BAY 1841788, Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients No dispute reported 06/30/2026 1225402495
Principal investigator 1 Janssen Research & Development, LLC $26,904.00 06/06/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Ca No dispute reported 06/30/2026 1175380385
Principal investigator 1 Janssen Research & Development, LLC $14,957.00 06/02/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-m No dispute reported 06/30/2026 1175380658
Principal investigator 1 Janssen Research & Development, LLC $1,464.00 05/19/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175380376
Principal investigator 1 Janssen Research & Development, LLC $34,000.00 05/19/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175380625
Principal investigator 1 Janssen Research & Development, LLC $25,048.00 05/12/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175380472
Principal investigator 1 Sumitomo Pharma America, Inc. $6,487.50 05/07/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP PA
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176634265
Principal investigator 1 Sumitomo Pharma America, Inc. $3,937.50 05/07/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP PA
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176634274
Principal investigator 1 Janssen Research & Development, LLC $46,527.00 04/28/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380640
Principal investigator 1 Janssen Research & Development, LLC $7,412.00 04/25/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175380754
Principal investigator 1 Janssen Research & Development, LLC $475.00 04/10/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380171
Principal investigator 1 Janssen Research & Development, LLC $541.00 04/10/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380270
Principal investigator 1 Janssen Research & Development, LLC $890.00 04/10/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380531
Principal investigator 1 Janssen Research & Development, LLC $200.00 04/10/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380577
Principal investigator 1 Sumitomo Pharma America, Inc. $1,252.50 04/09/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP PA
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176632783
Principal investigator 1 Sumitomo Pharma America, Inc. $13,972.50 04/09/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP PA
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176632803
Principal investigator 1 Janssen Research & Development, LLC $10,639.00 04/07/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175380286
Principal investigator 1 Janssen Research & Development, LLC $38,501.00 04/07/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380744
Principal investigator 1 Janssen Research & Development, LLC $382.00 03/31/2025 Non-covered Recipient Entity
GU RESEARCH NETWORK LLC
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy No dispute reported 06/30/2026 1175346870
Principal investigator 1 Janssen Research & Development, LLC $13,597.00 03/27/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380690
Principal investigator 1 Janssen Research & Development, LLC $650.00 03/14/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380178
Principal investigator 1 Janssen Research & Development, LLC $541.00 03/14/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380218
Principal investigator 1 Janssen Research & Development, LLC $13,597.00 03/14/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380233
Principal investigator 1 Janssen Research & Development, LLC $13,939.00 03/14/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380315
Principal investigator 1 Janssen Research & Development, LLC $342.00 03/14/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380322
Principal investigator 1 Janssen Research & Development, LLC $200.00 03/14/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380340
Principal investigator 1 Janssen Research & Development, LLC $200.00 03/14/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380361
Principal investigator 1 Janssen Research & Development, LLC $342.00 03/14/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380394
Principal investigator 1 Janssen Research & Development, LLC $200.00 03/14/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380487
Principal investigator 1 Janssen Research & Development, LLC $13,939.00 03/14/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380614
Principal investigator 1 Janssen Research & Development, LLC $200.00 03/14/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380698
Principal investigator 1 Janssen Research & Development, LLC $14,043.00 03/10/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380250
Principal investigator 1 Janssen Research & Development, LLC $8,483.00 03/10/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175380707
Principal investigator 1 Janssen Research & Development, LLC $36,638.00 02/10/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380713
Principal investigator 1 Janssen Research & Development, LLC $533.00 02/03/2025 Non-covered Recipient Entity
GU RESEARCH NETWORK LLC
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy No dispute reported 06/30/2026 1175346974
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,500.00 01/30/2025 Non-covered Recipient Entity
Wichita Urology Group PA
BAY 1841788, Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients No dispute reported 06/30/2026 1225405258
Principal investigator 1 Janssen Research & Development, LLC $525.00 01/24/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380156
Principal investigator 1 Janssen Research & Development, LLC $200.00 01/24/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380204
Principal investigator 1 Janssen Research & Development, LLC $200.00 01/24/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380277
Principal investigator 1 Janssen Research & Development, LLC $200.00 01/24/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380309
Principal investigator 1 Janssen Research & Development, LLC $200.00 01/24/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380354
Principal investigator 1 Janssen Research & Development, LLC $200.00 01/24/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380405
Principal investigator 1 Janssen Research & Development, LLC $200.00 01/24/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380429
Principal investigator 1 Janssen Research & Development, LLC $200.00 01/24/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380454
Principal investigator 1 Janssen Research & Development, LLC $200.00 01/24/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380494
Principal investigator 1 Janssen Research & Development, LLC $200.00 01/24/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380555
Principal investigator 1 Janssen Research & Development, LLC $200.00 01/24/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380736
Principal investigator 1 Janssen Research & Development, LLC $1,078.00 01/23/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380265
Principal investigator 1 Janssen Research & Development, LLC $212.00 01/23/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380368
Principal investigator 1 Janssen Research & Development, LLC $2,769.00 01/23/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380584
Principal investigator 1 AstraZeneca Pharmaceuticals LP $161,396.40 01/16/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP, PA
a phase 3b,open label,single arm,multi center,US study of bacillus calmette guerin bcg administered in combination with durvalumab in adult bcg naive,high risk non muscle invasive bladder cancer participants patapsco No dispute reported 06/30/2026 1185547907
Principal investigator 1 Janssen Research & Development, LLC $86,302.00 01/02/2025 Non-covered Recipient Entity
WICHITA UROLOGY GROUP
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175380513